Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone832-384-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.12 million
Profitability
Miscellaneous
Employees173
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions
What is Bellicum Pharmaceuticals' stock symbol?
Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."
How were Bellicum Pharmaceuticals' earnings last quarter?
Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) announced its quarterly earnings data on Monday, August, 5th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by $0.04. The biopharmaceutical company earned $1.39 million during the quarter, compared to analyst estimates of $0.23 million. Bellicum Pharmaceuticals had a negative net margin of 4,081.44% and a negative return on equity of 169.33%. View Bellicum Pharmaceuticals' Earnings History.
When is Bellicum Pharmaceuticals' next earnings date?
Has Bellicum Pharmaceuticals been receiving favorable news coverage?
News stories about BLCM stock have been trending somewhat negative on Saturday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Bellicum Pharmaceuticals.
Are investors shorting Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,130,000 shares, a decrease of 45.9% from the August 30th total of 2,090,000 shares. Based on an average trading volume of 736,100 shares, the days-to-cover ratio is presently 1.5 days. Approximately 2.6% of the company's stock are short sold. View Bellicum Pharmaceuticals' Current Options Chain.
Who are some of Bellicum Pharmaceuticals' key competitors?
Some companies that are related to Bellicum Pharmaceuticals include Cerecor (CERC), Axovant Sciences (AXON), AVEO Pharmaceuticals (AVEO), Calithera Biosciences (CALA), REDHILL BIOPHAR/S (RDHL), Arcturus Therapeutics (ARCT), Northwest Biotherapeutics (NWBO), Avadel Pharmaceuticals (AVDL), Harrow Health (HROW), American Brivision (Holding) (ABVC), MEI Pharma (MEIP), Generex Biotechnology (GNBT), Mustang Bio (MBIO), Sesen Bio (SESN) and CytoDyn (CYDY).
What other stocks do shareholders of Bellicum Pharmaceuticals own?
Who are Bellicum Pharmaceuticals' key executives?
Bellicum Pharmaceuticals' management team includes the folowing people:
- Mr. Richard A. Fair, Pres, CEO & Director (Age 50)
- Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)
- Mr. Thomas J. Farrell, Consultant (Age 56)
- Mr. Atabak Mokari, Chief Financial Officer (Age 42)
- Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller
When did Bellicum Pharmaceuticals IPO?
(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.
How do I buy shares of Bellicum Pharmaceuticals?
Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Bellicum Pharmaceuticals' stock price today?
One share of BLCM stock can currently be purchased for approximately $0.80.
How big of a company is Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals has a market capitalization of $37 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals.
What is Bellicum Pharmaceuticals' official website?
How can I contact Bellicum Pharmaceuticals?
Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected]
MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)
MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
